PCSK9 抑制剂相关研究进展

月环 杨(内蒙古医科大学 , 中国)
璐莎 鄂(内蒙古自治区人民医院心血管内科 , 中国)

摘要

前蛋白转化酶枯草溶菌素9（proprotein convertase subtilisin kexin type9, PCSK9）是一种丝氨酸蛋白酶, 其作用机制是与低密度脂蛋白胆固醇受体（LDLR）结合, 导致LDLR构象改变被自身降解, 从而使血浆低密度脂蛋白胆固醇发生蓄积, 引发动脉粥样硬化。近年来, 备受关注的靶向药物PCSK9抑制剂的诞生, 有效针对PCSK9进行精准调控, 使得低密度脂蛋白胆固醇水平下降。论文从PCSK9的结构、作用机制及PCSK9抑制剂的种类、应用现状及发展前景进行综述。

关键词

PCSK9；血脂；动脉粥样硬化；PCSK9抑制剂

参考

DawsonL P, Lum M, Nerleker N, et al. Coronary Atherosclerotic Plaque Regression:JACCState-of-the-ArtReview[J]. J Am Coll Cardiol,2022,79(1):66-82.

中国心血管健康与疾病报告 2021 概 要 [J]. 心脑血管病防治 ,2022,22(4):20-36+40.

Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture[J]. J Intern Med,2014,276(6):618-632.

Camaré C, Pucelle M, Nègre-Salvayre A, et al. Angiogenesis in the atherosclerotic plaque.[J]. Redox Biol,2017,8(12):18-34.

Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/KexinType9 Antibodies in Adults With Hypercholesterolemia:ASystematic Review and Metaanalysis[J]. AnnIntMed,2015,163(1):40-51.

Lee S, Lee HC, Kwon YW, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes[J]. Cell Metab,2014,19(3):484-497.

ABIFADE M,VARRET M, RABES JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nat Genet,2003,34(2):154-156.

ALLARD D, AMSELLEM S, ABIFADEL M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia[J]. Hum Mutat,2005.

LAGACE TA, CURTIS DE, GARUTI R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.

Ragusa R, Basta G, Neglia D, et al. PCSK9 and atherosclerosis: Looking beyond LDL regulation[J]. Eur J Clin Invest,2021,51(4):3459.

ZIJLSTRA L E, MOOIJAART S P, JUKEMA J W. PCSK9 inhibition i n high-risk patients [J]. Aging,2019,11(23):10791-10792.

Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic inter ventions: a systematic review and meta-analysis[J]. JAMA,2016,316(12):1289-1297.

Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/

AHA guideli ne on the treatment of blood cholesterol to reduce

atherosclerotic cardiov ascular risk in adults:a report of the American College of Cardiology/A merican Heart Association Task Force on Practice Guidelines[J]. Circul ation,2014,129(25):1-45.

Collins R, Reith C, Emberson J, et al.Interpretationoftheevidencefortheefficacyandsafetyofstatintherapy[J]. Lancet,2016,388(10059):2532-2561.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guideli nes for the management of dyslipidaemias: lipid modification to redu ce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.

FDA. Evolocumab (Repatha ®) label[EB/OL]. Washington DC (USA):FDA,2021-02-26[2022-07-22].

FDA. Alirocumab (Praluent ®) lable[EB/OL]. Washington DC (USA):FDA,2015-07-24[2022-07-22].

Roth EM, Davidson MH. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Rev Cardiovasc Med,2018,19(S1):31-46.

Enrique G, Aner D, Chaim Y. Statins and PCSK9 inhibitors: A new lipid-lowering therapy[J]. European Journal of Pharmacology,2020,878:173114.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015,372(25):2387-2397.

NICHOLLS S J, NISSEN S E, PRATI F, et al. Assessing the

impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography:rationale and design of the

randomized,placebo-controlled HUYGENS study[J]. Cardiovasc

Diagn Ther,2021,11(1):120-129.

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with card iovascular disease[J]. N Engl J Med,2017,3.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v5i12.12308